Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968341 | 1.00 | PIK3CD (0.34) | PIK3CDPIK3CAKCNK3SSTR4RIPK1 | |
| SCHEMBL24968338 | 0.91 | PIK3CD (0.35) | PIK3CDPIK3CAKCNK3SSTR4RIPK1 | |
| SCHEMBL27233855 | 0.91 | PIK3CD (0.35) | PIK3CDPIK3CAKCNK3SSTR4RIPK1 | |
| SCHEMBL24968934 | 0.91 | PIK3CD (0.35) | PIK3CDPIK3CAKCNK3SSTR4RIPK1 | |
| SCHEMBL24968383 | 0.85 | TACR1 (0.35) | PIK3CDPIK3CAKCNK3SSTR4RIPK1 | |
| SCHEMBL24968385 | 0.83 | CYP11B1 (0.36) | PIK3CDPIK3CAKCNK3SSTR4RIPK1 | |
| SCHEMBL24968342 | 0.82 | HCRTR1 (0.36) | PIK3CAPIK3R1CFTR | |
| SCHEMBL27233713 | 0.80 | TIPARP (0.47) | — | |
| SCHEMBL24968213 | 0.78 | SLC6A2 (0.44) | PIK3CDPIK3CAKCNK3SSTR4RIPK1 | |
| SCHEMBL24968932 | 0.76 | AR (0.45) | PIK3CDPIK3CAPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | PIK3CD 753/4885PIK3CA 585/4885KCNK3 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.